APA (7th ed.) Citation

Koga, T., Takemori, S., Hagimori, N., Morimoto, S., Sumiyoshi, R., Shimizu, T., . . . Kawakami, A. (2020). An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant). Medicine (Baltimore), 99(50), e23291. https://doi.org/10.1097/MD.0000000000023291

Chicago Style (17th ed.) Citation

Koga, Tomohiro, et al. "An Open-label Continuation Trial of Sirolimus for Tocilizumab-refractory Idiopathic Multicentric Castleman Disease: Study Protocol for an Investigator-initiated, Multicenter, Open-label Trial (SPIRIT Compliant)." Medicine (Baltimore) 99, no. 50 (2020): e23291. https://doi.org/10.1097/MD.0000000000023291.

MLA (9th ed.) Citation

Koga, Tomohiro, et al. "An Open-label Continuation Trial of Sirolimus for Tocilizumab-refractory Idiopathic Multicentric Castleman Disease: Study Protocol for an Investigator-initiated, Multicenter, Open-label Trial (SPIRIT Compliant)." Medicine (Baltimore), vol. 99, no. 50, 2020, p. e23291, https://doi.org/10.1097/MD.0000000000023291.